ÉúÎïͨ±¨µÀ µÚ¶þ¾üÒ½´óѧ¡¢Öйúҽѧ¿ÆÑ§ÔºµÄÑо¿ÈËԱ֤ʵ£¬Ö×ÁöÍâÃÚÌåRNAsͨ¹ý¼¤»î·ÎÅÝÉÏÆ¤TLR3ÕÐļÖÐÐÔÁ£Ï¸°û´Ù½øÁË·Î×ªÒÆÇ°Î¢»·¾³ÐγÉ¡£ÕâÒ»Ñо¿·¢ÏÖ·¢²¼ÔÚ8ÔÂ8Èյġ¶°©Ï¸°û¡·£¨Cancer Cell£©ÔÓÖ¾ÉÏ¡£

ÎÒ¹úÖøÃûµÄÃâÒßѧ¼Ò²ÜÑ©ÌΣ¨Xuetao Cao£©ÔºÊ¿ÊÇÕâÆªÂÛÎĵÄͨѶ×÷Õß¡£²ÜÑ©ÌÎÏÖÈÎÖ°Õã½­´óѧҽѧԺ¡¢Öйúҽѧ¿ÆÑ§Ôº¡¢µÚ¶þ¾üÒ½´óѧ£¬Ö÷Òª´ÓÊÂÖ×ÁöÃâÒßÖÎÁƺͷÖ×ÓÃâÒßѧ·½ÃæµÄÑо¿£¬ÔøÔÚÊ÷ͻ״ϸ°ûµÄÃâÒßѧºÍÖ×ÁöµÄÃâÒßÓë»ùÒòÖÎÁÆÑо¿·½Ãæ»ñµÃÖØÒª³É¹û£¬ÒÔͨѶ×÷ÕßµÄÉí·ÝÔÚNature Immunology¡¢Nature Communications¡¢ImmunityµÈ¹úÄÚÍâÖªÃûÔÓÖ¾·¢±íÂÛÎÄ200¶àƪ¡£2013Ä굱ѡΪCellÔÓÖ¾µÄ±àί¡£

°©Ö¢ÊÇÓɶàÖÖϸ°û¡¢Òò×Ó¹²Í¬×÷ÓòúÉúµÄ£¬Ëü´æÔÚÓÚÒ»¸ö¸´ÔÓµÄϸ°ûÉú̬ϵͳÖУ¬¼´Ö×Áö΢»·¾³¡£ÔÚÖ×Áö×ªÒÆ¹ý³ÌÖУ¬Î¢»·¾³¶ÔÓÚ×ªÒÆµÄÖ×Áöϸ°ûµÄ´æ»îÓëÔöÖ³¶¼ÊDZØÐèµÄ¡£ÒÑÓÐÑо¿±íÃ÷Ö×Áöϸ°ûµÄ×ªÒÆ¾ßÓÐÆ÷¹ÙÌØÒìÐÔ£¬ËµÃ÷ÌØ¶¨µÄÆ÷¹Ù¿ÉÄܾßÓиüÊʺÏÖ×Áöϸ°û×ªÒÆµÄ»·¾³¡£Ñо¿Ö×ÁöµÄ·Ö×Ó»·¾³ÓÐÖúÓÚÕÒ³öһЩ¿ÉÒÔ×èÖ¹Ö×Áöϸ°û×ªÒÆµÄаеã¡£

Ë÷È¡microRNA¸ßͨÁ¿¼ì²â²ÉÓÃÀûÆ÷pCRоƬ£ºExiqon microRNA qpCR panelµÄÏêϸ×ÊÁÏ

·Î°©Êǵ±½ñÈ«Çò·¶Î§ÄÚΣº¦ÐÔ×î´óµÄ¼²²¡Ö®Ò»£¬¸ß·¢²¡Âʺ͸ßÖÂËÀÂÊʹÆä³ÉΪ¡°ÉúÃüɱÊÖ¡±¡£¾ÝÊÀ½çÎÀÉú×é֯ͳ¼Æ£¬·Î°©µÄ5Äê´æ»îÂʽöΪ15%¡£¶øÇÒ£¬Ëæ×ÅÎüÑÌÈËÊýµÄ²»¶ÏÉÏÉýºÍ»·¾³µÄ³ÖÐø¶ñ»¯£¬·Î°©·¢²¡ÂʳÊÉÏÉýÇ÷ÊÆ¡£ÔÚÎÒ¹ú£¬Ã¿ÄêÔ¼ÓÐ40ÍòÈËËÀÓڷΰ©¡£¶àÄêµÄÑо¿Ö¤Êµ£¬·Î°©µÄ·¢Éú·¢Õ¹¼°ÇÖÏ®×ªÒÆ³ýÁ˺ͷΰ©µÄ×ÔÉíÌØÐÔÏà¹Ø£¬Ò²ºÍ·Î°©Î¢»·¾³ÓÐ×ÅÃÜÇеĹØÏµ¡£

ÔÚÕâÆªÎÄÕÂÖÐÑо¿ÈËԱ֤ʵ£¬·ÎÉÏÆ¤Ï¸°ûͨ¹ýTLR3¸ÐÖªÖ×ÁöÍâÃÚÌåRNAs£¬¶ÔÓÚÆô¶¯ÖÐÐÔÁ£Ï¸°ûÕÐļ¼°·Î×ªÒÆÎ¢»·¾³ÐÎ³ÉÆðÖÁ¹ØÖØÒªµÄ×÷Óá£ÔÚ×Ô·¢ÐÔ×ªÒÆÄ£ÐÍÖÐTLR3ȱÏÝСÊóÏÔʾ·Î×ªÒÆ¼õÉÙ¡£»úÖÆÑо¿Ö¤Êµ£¬Ô­·¢Ö×ÁöÀ´Ô´µÄÍâÃÚÌåRNAs¸»º¬Ð¡ºËRNA£¨small nuclear RNAs£¬snRNAs£©£¬ÔÚ·ÎÉÏÆ¤Ï¸°ûÖ줻îTLR3£¬ÓÉ´ËÓÕµ¼ÁË·ÎÔàÖеÄÇ÷»¯Òò×Ó·ÖÃÚ£¬´Ù½øÁËÖÐÐÔÁ£Ï¸°ûÕÐļ¡£

ÐÂÑо¿¼ø±ð³öÁËÖ×ÁöÍâÃÚÌåRNAsºÍËÞÖ÷·ÎÉÏÆ¤Ï¸°ûTLR3¼¤»îÕâÒ»×ªÒÆÐźÅÖᣬΪ¿ØÖư©Ö¢·Î×ªÒÆÌṩÁËDZÔڵİеã¡£

ͬ¼Ã´óѧÉúÃü¿ÆÑ§Óë¼¼ÊõѧԺºÍÉϺ£ÊзοÆÒ½ÔºÁÙ´²×ª»¯ÖÐÐÄÕÅ·«¿ÎÌâ×éÔÚ¡¶Oncotarget¡·ÔÓÖ¾ÉÏ·¢±íÑо¿³É¹û,Ê״νÒʾÁË×éµ°°×È¥¼×»ù»¯Ã¸KDM1A/LSD1´Ù½ø·ÇСϸ°û·Î°©ÇÖÏ®ºÍ×ªÒÆµÄÒ»¸öлúÖÆ£ºKDM1Aͨ¹ýÒÆ³ýÌØÒìµÄ×éµ°°×ÐÞÊÎH3K4me2À´³ÁĬTIMp3£¨Ò»ÖÖ»ùÖʽðÊôµ°°×øµÄÒÖÖÆµ°°×£©»ùÒòµÄת¼, µ¼ÖÂϸ°ûÍâ»ùÖÊ£¨ECM£©ÖлùÖʽðÊôµ°°×øMMp2µÄ±í´ïÔö¼Ó£¬ºÍϸ°ûÄÚJNKµ°°×¼¤Ã¸»îÐÔµÄÔöÇ¿£¬´Ó¶ø´Ù½ø·ÇСϸ°û·Î°©µÄÇÖÏ®ºÍ×ªÒÆ(ͬ¼Ã´óѧOncotarget·¢±íÎÄÕ½âÎö°©Ö¢ÇÖÏ®×ªÒÆÐ»úÖÆ )¡£

2015Äê3ÔÂ25ÈÕ£¬Ç廪´óѧÂÞÓÀÕ¿ÎÌâ×éµÄÑо¿ÈËÔ±ÔÚ¹ú¼Ê°©Ö¢Ñо¿ÁìÓòÖøÃûÆÚ¿¯¡¶Clinical Cancer Research¡··¢±íÁËÒ»ÏîÑо¿³É¹û£¬²ûÃ÷ÁËmiR-30s¶Ô·Î°©×ªÒÆÇ°Î¢Éú¾³µÄÒ»ÖÖÐÂÐ͵÷½Ú»úÖÆ£¬±íÃ÷miR-30s²»½öÊǷΰ©¿¹×ªÒÆÖÎÁÆÒ»ÖÖÓÐǰ¾°µÄ°Ð±ê£¬¶øÇÒ»¹ÊǷΰ©×ªÒƵÄÖ¸±ê(Ç廪½ÌÊÚ¡¶ClinicalCancerResearch¡··¢±í·Î°©Ð³ɹû )¡£

2014Ä꣬Ìì½òÒ½¿Æ´óѧ¡¢µÂ¿ËÈøË¹´óѧÎ÷ÄÏҽѧÖÐÐĵÄÑо¿ÈËԱ֤ʵ£¬ Aiolosͨ¹ý³ÁĬp66Shcת¼´Ù½øÁ˰©Ï¸°û·ÇÌù±ÚÒÀÀµÐÔ£¨Anchorage Independence£©Éú³¤ºÍ×ªÒÆ¡£ÕâÒ»Ñо¿·¢ÏÖ·¢±íÔÚCancer cellÔÓÖ¾ÉÏ(Ìì½òÒ½¿Æ´óѧCancercell·¢±í°©Ö¢ÐÂÎÄÕ )¡£

£¨ÉúÎïͨ£ººÎæÍ£©

ÉúÎïÍ¨ÍÆ¼öÔ­ÎÄÕªÒª£º

Tumor Exosomal RNAs promote Lung pre-metastatic Niche Formation by Activating Alveolar Epithelial TLR3 to Recruit Neutrophils

The pre-metastatic niche educated by primary tumor-derived elements contributes to cancer metastasis. However, the role of host stromal cells in metastatic niche formation and organ-specific metastatic tropism is not clearly defined. Here, we demonstrate that lung epithelial cells are critical for initiating neutrophil recruitment and lung metastatic niche formation by sensing tumor exosomal RNAs via Toll-like receptor 3 (TLR3). TLR3-deficient mice show reduced lung metastasis in the spontaneous metastatic models. Mechanistically, primary tumor-derived exosomal RNAs, which are enriched in small nuclear RNAs, activate TLR3 in lung epithelial cells, consequently inducing chemokine secretion in the lung and promoting neutrophil recruitment. Identification of metastatic axis of tumor exosomal RNAs and host lung epithelial cell TLR3 activation provides potential targets to control cancer metastasis to the lung.

×÷Õß¼ò½é£º

²ÜÑ©ÌÎԺʿ¼òÀú£¨2016Äê8ÔÂ19ÈÕ¸üУ©

²ÜÑ©ÌΣ¬Öйúҽѧ¿ÆÑ§ÔºÔº³¤¡¢±±¾©Ð­ºÍҽѧԺУ³¤¡£1964Äê³öÉú£¬1981Ä꿼ÈëµÚ¶þ¾üÒ½´óѧ£¬1986Äê±¾¿Æ±ÏÒµºó¹¥¶ÁÃâÒßѧ˶ʿ£¬1990Äê»ñ²©Ê¿Ñ§Î»¡£±ÏÒµºóÁôУÈν²Ê¦£¬92Äê½úÉý½ÌÊÚ£¬96Äê½úÉý²©µ¼£¬2004ÄêÈεڶþ¾üÒ½´óѧ¸±Ð£³¤£¬2005Ä굱ѡÖйú¹¤³ÌԺԺʿ£¬ 2013Ä굱ѡµÂ¹ú¿ÆÑ§ÔºÍ⼮Ժʿ¡£ÏÖÈÎÑÇÌ«ÃâÒßѧÁªÃËÖ÷Ï¯ÃØÊ鳤£¨2013-2015µ£ÈÎÑÇÌ«ÃâÒßѧÁªÃËÖ÷ϯ£©¡¢ÖйúÃâÒßѧ»áÃØÊ鳤£¨2006-2015µ£ÈÎÖйúÃâÒßѧ»áÀíʳ¤£©¡¢Ò½Ñ§ÃâÒßѧ¹ú¼ÒÖØµãʵÑéÊÒÖ÷ÈΡ£ÔøÈÎÈ«ÇòÂýÐÔ¼²²¡·À¿ØÁªÃËÖ÷ϯ£¨2013-2015£©£¬2000Äê´´½¨Õã½­´óѧÃâÒßѧÑо¿Ëù²¢µ£ÈÎËù³¤¡£²ÜÑ©ÌÎԺʿÊǹú¼Ò½Ü³öÇàÄê¿ÆÑ§»ù½ð»ñµÃÕß¡¢¡°³¤½­¼Æ»®¡±ÌØÆ¸½ÌÊÚ£¬¹ú¼Ò973ÃâÒßѧÏîÄ¿Ê×ϯ¿ÆÑ§¼Ò£¬¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÃâÒßÑ§ÖØ´óÏîÄ¿ºÍ´´ÐÂÍŶÓÏîÄ¿¸ºÔðÈ˺͹úÎñԺѧλÆÀÒéίԱ»á»ù´¡Ò½Ñ§Ñ§¿ÆÆÀÒé×éÕÙ¼¯ÈË¡£´´°ì¡¶ÖйúÖ×ÁöÉúÎïÖÎÁÆÔÓÖ¾¡·²¢ÈÎÖ÷±à£¬Cellular and Molecular Immunology¹²Í¬Ö÷±à¡¢ÈÎJournal of Molecular Medicine¡¢Gene Therapy¡¢Cancer Immunology Research¸±Ö÷±à, ÈÎCell¡¢Annual Review of Immunology¡¢Science Translational Medicine, Science Advances, eLifeµÈ±àί¡£

²ÜÑ©ÌÎԺʿÖ÷Òª´ÓÊÂÌìÈ»ÃâÒßÓëÑ×Ö¢»ù´¡Ñо¿¡¢Ö×ÁöÃâÒßÖÎÁÆÓ¦ÓÃÑо¿¡£2004Äê·¢ÏÖÁËÊ÷ͻ״ϸ°ûÐÂÐÍÑÇȺ¶ø·¢±íÁ˹úÄÚµÚһƪNature ImmunologyÂÛÎÄ¡£ÒÔͨѶ×÷ÕßÔÚCell¡¢Nature¡¢Science¡¢Nature Immunology¡¢Cancer Cell¡¢ImmunityµÈ·¢±íSCIÂÛÎÄ230ÓàÆª¡£SCIËûÒý8000Óà´Î¡£ÒÔµÚÒ»Íê³ÉÈË»ñ¹ú¼Ò×ÔÈ»¿ÆÑ§¶þµÈ½±1Ïî (2003)¡¢ÖлªÒ½Ñ§¿Æ¼¼½±Ò»µÈ½±2Ïî¡¢¾ü¶Ó¿Æ¼¼½ø²½Ò»µÈ½±1Ïî¡¢ÉϺ£ÊпƼ¼½ø²½Ò»µÈ½±1Ïî¡¢ÉϺ£ÊÐ×ÔÈ»¿ÆÑ§Ò»µÈ½±4ÏÒÑ»ñµÃ¹ú¼Ò·¢Ã÷רÀû16Ï»ñµÃ¹ú¼ÒIIÀàÐÂÒ©Ö¤Êé2¸ö¡£»ñµÃÖйú¹¤³ÌÔº¹â»ª¹¤³Ì½±¡¢Öйú¿ÆÑ§Ôº³Â¼Î¸ý¿ÆÑ§½±¡¢Ê×½ìÊ÷À¼Ò½Ñ§½±³É¾Í½±¡¢½ÌÓý²¿****³É¾Í½±¡¢ÖйúÇàÄê¿ÆÑ§¼Ò½±µÈ¡£Ö÷±à¡¶Ò½Ñ§ÃâÒßѧ¡·±¾¿ÆÉú¡¢Ñо¿Éúͳ±à½Ì²Ä£¬ÅàÑøµÄ12Ãû²©Ê¿Éú»ñµÃÈ«¹úÓÅÐ㲩ʿÂÛÎÄ£¬»ñµÃÊ×½ìÖйúÑо¿Éú½ÌÓýÌØµÈ½±£¨2014£©ºÍNatureÖÕÉíµ¼Ê¦³É¾Í½±£¨2015£©¡£